Product info
Product name: PT-141
Alias:Bremelanotide; BREMELANOTIDE; Brmelanotice; Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH; Bremelanotide, PT141,PT-141; BREMELANOTIDE PT141; Brmelanotide; PT141
CAS: 32780-32-8
MF: C50H69N15O10
MW: 1040.17736
Appearance: Freeze-dried powder
Water Content(Karl Fischer): ≤ 5.0%
Acetate Content(by HPLC): ≤ 15.0%
Amino Acid Composition: ± 10% of theoretical
Purity(by HPLC): ≥ 97.0%
Single Impurity(by HPLC): ≤ 1.0%
Peptide Content(by %N): ≥ 80%
Assay(By Anhydrous, Acetic Acid-free): 95.0~105.0%
Bacterial Endotoxins: ≤ 5EU/mg
MS(ESI):Consistent
Mass Balance:95.0~105.0%
PT-141 Usage
PT-141 in Men:
Effective in a broad range of patients, including those with severe ED and those non-responsive to sildenafil, effcacy in “at-home” studies is comparable to PDE-5 inhibitors up to 50% of ED patients were restored to a normal level of function coadministration with sildenafil shows superior efficacy side effects include facial flushing, nausea, aftertaste and post-nasal drip
PT-141 in Women:
Palatin conducted a Phase 2A study in 18 premenopausal women with a diagnosis of female sexual dysfunction (FSD). Patients reported a significant increase in sexual desire and in genital arousal after receiving PT-141, compared to placebo. Additionally, there was a correlation between sexual desire and genital arousal in patients receiving PT-141, an observation that further reinforces the potential importance of these reports.
Male rats have shown erectile response with doses as low as 1-2 mgs whereas most female rats have shown positive results with higher doses around 2-3 mgs. While the dosage requirements tend to be higher for female rats, the observable results in female rats tend to be stronger.
Aimee
Sales Manager